Drugs & Targets FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer February 09, 2018Vol.44 No.06
Drugs & Targets Foundation Medicine and EORTC collaborate comprehensive genomic profiling February 09, 2018Vol.44 No.06
Drugs & Targets Abbott PathVysion HER-2 DNA Probe assay to be used in ANGLE study February 09, 2018Vol.44 No.06
Clinical Roundup In phase III study Tecentriq and Avastin reduced risk of disease worsening/death by 26 percent in advanced kidney cancer February 09, 2018Vol.44 No.06
Clinical Roundup Opdivo plus Yervoy meet PFS endpoint in phase III trial in frontline NSCLC February 09, 2018Vol.44 No.06
Clinical Roundup Tyme announces interim phase II data for SM-88 in prostate cancer at ASCO GU Symposium February 09, 2018Vol.44 No.06
In Brief Arap, Pasqualini named to leadership posts at Rutgers Cancer Institute of New Jersey at University Hospital in Newark February 09, 2018Vol.44 No.06
In Brief Dhodapkar named director of new Center for Cancer Immunology at Emory Winship February 09, 2018Vol.44 No.06
In Brief Oberstein named director of GI medical oncology at NYU Perlmutter Cancer Center February 09, 2018Vol.44 No.06
